Immunocore (IMCR) Competitors $31.70 +0.87 (+2.82%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IMCR vs. ELAN, CYTK, NUVL, BPMC, KRYS, BHVN, RNA, RARE, ACLX, and OGNShould you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Elanco Animal Health (ELAN), Cytokinetics (CYTK), Nuvalent (NUVL), Blueprint Medicines (BPMC), Krystal Biotech (KRYS), Biohaven (BHVN), Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Arcellx (ACLX), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry. Immunocore vs. Elanco Animal Health Cytokinetics Nuvalent Blueprint Medicines Krystal Biotech Biohaven Avidity Biosciences Ultragenyx Pharmaceutical Arcellx Organon & Co. Immunocore (NASDAQ:IMCR) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends, community ranking and institutional ownership. Does the media prefer IMCR or ELAN? In the previous week, Elanco Animal Health had 30 more articles in the media than Immunocore. MarketBeat recorded 32 mentions for Elanco Animal Health and 2 mentions for Immunocore. Immunocore's average media sentiment score of 0.15 beat Elanco Animal Health's score of 0.10 indicating that Immunocore is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elanco Animal Health 4 Very Positive mention(s) 0 Positive mention(s) 26 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is IMCR or ELAN more profitable? Immunocore has a net margin of -19.16% compared to Elanco Animal Health's net margin of -27.94%. Elanco Animal Health's return on equity of 7.29% beat Immunocore's return on equity.Company Net Margins Return on Equity Return on Assets Immunocore-19.16% -14.68% -6.68% Elanco Animal Health -27.94%7.29%3.14% Which has more volatility and risk, IMCR or ELAN? Immunocore has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Do insiders and institutionals hold more shares of IMCR or ELAN? 84.5% of Immunocore shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 9.1% of Immunocore shares are held by company insiders. Comparatively, 0.6% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable earnings and valuation, IMCR or ELAN? Immunocore has higher earnings, but lower revenue than Elanco Animal Health. Immunocore is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunocore$249.43M6.36-$55.29M-$1.08-29.35Elanco Animal Health$4.49B1.39-$1.23B-$2.55-4.94 Does the MarketBeat Community favor IMCR or ELAN? Elanco Animal Health received 72 more outperform votes than Immunocore when rated by MarketBeat users. However, 74.12% of users gave Immunocore an outperform vote while only 54.44% of users gave Elanco Animal Health an outperform vote. CompanyUnderperformOutperformImmunocoreOutperform Votes6374.12% Underperform Votes2225.88% Elanco Animal HealthOutperform Votes13554.44% Underperform Votes11345.56% Do analysts rate IMCR or ELAN? Immunocore presently has a consensus target price of $74.36, suggesting a potential upside of 134.59%. Elanco Animal Health has a consensus target price of $17.00, suggesting a potential upside of 34.92%. Given Immunocore's stronger consensus rating and higher probable upside, equities analysts clearly believe Immunocore is more favorable than Elanco Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunocore 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.69Elanco Animal Health 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 SummaryImmunocore beats Elanco Animal Health on 10 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Immunocore News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCR vs. The Competition Export to ExcelMetricImmunocoreBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.59B$3.14B$5.39B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E Ratio-29.3512.18113.8115.12Price / Sales6.36332.371,483.2593.03Price / CashN/A148.6339.6434.05Price / Book4.274.024.665.02Net Income-$55.29M-$42.25M$119.06M$225.46M7 Day Performance-3.35%8.08%0.79%0.37%1 Month Performance1.96%8.72%5.65%3.57%1 Year Performance-31.87%32.11%36.76%29.42% Immunocore Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCRImmunocore2.2403 of 5 stars$31.70+2.8%$74.36+134.6%-30.1%$1.59B$249.43M-29.35497Upcoming EarningsELANElanco Animal Health4.1833 of 5 stars$12.65-1.0%$17.00+34.4%+45.7%$6.32B$4.42B-4.969,300Upcoming EarningsShort Interest ↓High Trading VolumeCYTKCytokinetics4.2656 of 5 stars$51.00-0.6%$83.93+64.6%+47.6%$6.04B$7.53M-9.50250Upcoming EarningsInsider SellingShort Interest ↓NUVLNuvalent3.2685 of 5 stars$88.49-1.9%$112.40+27.0%+66.2%$5.85BN/A-31.8340Insider SellingHigh Trading VolumeBPMCBlueprint Medicines2.2147 of 5 stars$87.51-1.9%$120.39+37.6%+51.4%$5.54B$434.42M-41.47640Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageKRYSKrystal Biotech4.639 of 5 stars$172.53-1.7%$196.75+14.0%+47.8%$5.04B$50.70M47.27229Upcoming EarningsBHVNBiohaven2.6476 of 5 stars$49.72-1.5%$61.92+24.5%+72.5%$4.77B$462.51M-5.43239RNAAvidity Biosciences2.2552 of 5 stars$42.26-2.2%$63.22+49.6%+717.8%$4.75B$9.56M-14.37190Analyst ForecastRAREUltragenyx Pharmaceutical4.1907 of 5 stars$50.99-1.6%$85.08+66.9%+41.5%$4.70B$481.30M-6.981,276Upcoming EarningsACLXArcellx1.4875 of 5 stars$84.27-2.9%$89.75+6.5%+150.6%$4.67B$110.32M-81.03130Analyst ForecastShort Interest ↑News CoverageOGNOrganon & Co.4.7021 of 5 stars$18.79+4.8%$21.33+13.6%+23.2%$4.62B$6.26B4.8310,000Dividend AnnouncementNews Coverage Related Companies and Tools Related Companies ELAN Competitors CYTK Competitors NUVL Competitors BPMC Competitors KRYS Competitors BHVN Competitors RNA Competitors RARE Competitors ACLX Competitors OGN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMCR) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
